Clinical Trials Logo

Clinical Trial Summary

Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant. We compared the effects of exergaming (EXE), balance (BAL), cycling (CYC), proprioceptive neuromuscular facilitation (PNF), and a standard care wait-listed control group (CON) on clinical and motor symptoms and quality of life (QoL) in people with MS (PwMS). Methods: PwMS (n = 68, 90% female; age, 47.0 yr; Expanded Disability Status Scale score 5-6) were randomized into five groups. Before and after the interventions (five times a week for 5 wk), PwMS were tested for MS-related clinical and motor symptoms (Multiple Sclerosis Impact Scale-29 (MSIS-29), primary outcome), QoL (EuroQol Five Dimensions Questionnaire), symptoms of depression, gait and balance ability (Tinetti Assessment Tool), static and dynamic balance and fall risk (Berg Balance Scale), walking capacity (6-min walk test), and standing posturography on a force platform. Patients were followed up for 2 years after 5 weeks of intensive care. Tests are performed every six months.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04550650
Study type Interventional
Source Somogy Megyei Kaposi Mór Teaching Hospital
Status Completed
Phase N/A
Start date April 6, 2018
Completion date September 1, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03455582 - Cognition Evolution and MRI Markers in PPMS Patients on 2 Years N/A
Active, not recruiting NCT04544449 - A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis Phase 3
Recruiting NCT04918225 - Motor Asymmetry in Progressive Multiple Sclerosis Patients
Completed NCT02913157 - Hydroxychloroquine in Primary Progressive Multiple Sclerosis Phase 2
Completed NCT01982942 - Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis Phase 2
Recruiting NCT05204459 - MS-ResearchBiomarkerS
Recruiting NCT05663853 - An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
Completed NCT01194570 - A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Phase 3
Completed NCT02305264 - Imaging of Intracerebral Inflammation in MS N/A
Completed NCT03679468 - Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation N/A
Recruiting NCT05496881 - Exercise Effects in Multiple Sclerosis N/A
Completed NCT02506751 - Open-label Study of Liothyronine in MS Phase 1
Temporarily not available NCT02606929 - Use of Well Known Drugs for New Destination - MS Improvement (MSNT) Phase 0
Completed NCT03424538 - The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients N/A
Completed NCT04545372 - Aerobic Exercises for Multiple Sclerosis N/A
Recruiting NCT05122559 - Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT02988401 - Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Phase 1/Phase 2
Completed NCT02632591 - Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment Phase 1
Completed NCT01917019 - A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Phase 3
Completed NCT01433497 - Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis Phase 3